Usmani, S Z
Sexton, R
Ailawadhi, S
Shah, J J
Valent, J
Rosenzweig, M
Lipe, B
Zonder, J A
Fredette, S
Durie, B
Hoering, A
Bartlett, B
Orlowski, R Z
Article History
First Online: 7 August 2015
Competing interests
: SZU is a consultant for Celgene, Millennium, Onyx and Sanofi; RZO is a consultant and has received research funding for ArrayBioPharma, Bristol-Myers Squibb, Celgene, Janssen, Millennium, Onyx and Pharmacyclics; SA received honorarium from Millennium. JS is a consultant to Celgene, Millennium, Onyx and Novartis and has received research funding for ArrayBioPharma, Celgene, Millennium, Onyx and Novartis. JV has received speaking honoraria from Celgene and Millennium. The remaining authors declare no conflict of interest.